Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroSearch has reported positive results from a Phase II study with ABT-894, a neuronal nicotinic receptor modulator, for the treatment of adults suffering from attention-deficit hyperactivity disorder.
Subscribe to our email newsletter
The Phase II study was a randomized, double-blind, and placebo-controlled dose-ranging study to evaluate the efficacy and safety of ABT-894 in approximately 200 adults with attention-deficit hyperactivity disorder (ADHD), and with atomoxetine as active control.
The ABT-894 compound was discovered by a joint scientific team from NeuroSearch and Abbott under collaboration between the two companies.
Results from the Phase II study show that ABT-894 was efficacious in adult ADHD measured as a statistically significant improvement on the primary endpoint, the total score of the Conners’s adult ADHD rating scales. ABT-894 and atomoxetine appeared to be comparable across efficacy measures.
In the study, ABT-894 was safe and generally well tolerated and demonstrated statistically significant efficacy compared to placebo in adults suffering from ADHD.
Flemming Pedersen, CEO in NeuroSearch, said: “We are very pleased by the positive results seen in this Phase II adult ADHD study with ABT-894 and excited about the prospects for this compound as a potential new treatment of ADHD.”